These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35935852)

  • 1. The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    Luo X; Zhou Z; Zeng X; Liu Q
    Front Pharmacol; 2022; 13():935581. PubMed ID: 35935852
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China.
    Zhou D; Luo X; Zhou Z; Zeng X; Wan X; Tan C; Liu Q
    Front Pharmacol; 2022; 13():880280. PubMed ID: 36091746
    [No Abstract]   [Full Text] [Related]  

  • 3. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma.
    Zhang L; Su H; Liang X; Chen X; Li Y
    Sci Rep; 2024 Jul; 14(1):17734. PubMed ID: 39085374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.
    Lang W; Ai Q; He Y; Pan Y; Jiang Q; Ouyang M; Sun T
    Int J Clin Pharm; 2024 Dec; 46(6):1536-1545. PubMed ID: 39276261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer.
    Shi Y; Qian D; Li Y; Chen W; Bo M; Zhang M; Shi J; Jia B; Dai Y; Li G
    Transl Cancer Res; 2023 Apr; 12(4):928-938. PubMed ID: 37180653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer.
    Zhang H; Li L; Feng L; Zhou Z; Zhang X; Feng J; Liu Q
    Adv Ther; 2023 Nov; 40(11):4945-4956. PubMed ID: 37715852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis.
    Shi Y; Pei R; Liu S
    Front Oncol; 2022; 12():833773. PubMed ID: 36324594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
    Liu Y; Shao R
    Front Pharmacol; 2024; 15():1225076. PubMed ID: 38813103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China.
    Liu H; Wang Y; He Q
    Health Econ Rev; 2022 Dec; 12(1):66. PubMed ID: 36581793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer.
    Pei Z; Xiao N; Yang P
    Front Pharmacol; 2023; 14():1265784. PubMed ID: 37964872
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
    He C; Mi X; Xu G; Xu X; Xin W; Zhong L; Zhu J; Shu Q; Fang L; Ding H
    PLoS One; 2024; 19(5):e0302961. PubMed ID: 38748691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.
    Liu G; Kang S; Wang X; Shang F
    Front Oncol; 2021; 11():669195. PubMed ID: 33987103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.
    Zhao M; Shao T; Chi Z; Tang W
    Front Public Health; 2023; 11():1051484. PubMed ID: 36908446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective.
    Li W; Wan L; Zhang J
    Expert Rev Gastroenterol Hepatol; 2024 Jun; 18(6):293-301. PubMed ID: 38923910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.
    Tang YK; Xu Z; Ye ZM; Li SR; Zhou Q
    Head Neck; 2024 Jan; 46(1):5-14. PubMed ID: 37846175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis.
    Wu B; Lu S
    Transl Lung Cancer Res; 2020 Oct; 9(5):1770-1784. PubMed ID: 33209600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
    Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
    BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China.
    Zhou C; Wei J; Xu K; Lin Y; Zhang L; Li X
    Risk Manag Healthc Policy; 2023; 16():2447-2458. PubMed ID: 38024498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.